Breast Cancer Research and Treatment

, Volume 98, Issue 1, pp 91–98 | Cite as

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype

  • Füsun Baba
  • Kathryn Swartz
  • Regina van Buren
  • Jens Eickhoff
  • Yong Zhang
  • William Wolberg
  • Andreas Friedl
Preclinical study


Members of the syndecan and glypican families of cell surface heparan sulfate proteoglycans (HSPGs) are modulators of growth factor signaling and cell adhesion. Both loss and gain in expression of syndecans and glypicans has been associated with malignant progression. The goal of this project was to investigate a possible relationship between expression of cell surface HSPGs (syndecan-1, syndecan-4 and glypican-1) and established prognostic factors or clinical outcome in breast carcinomas. Tissue arrays containing 207 human breast carcinoma samples in duplicate were immuno-labeled with antibodies to syndecan-1, syndecan-4, glypican-1, Ki67, E-cadherin, estrogen receptor (ER) and progesterone receptor (PR). Clinical follow-up information was available for up to 18.6 years (median follow-up 6.2 years). Syndecan-1 and syndecan-4 expression in carcinoma cells ranged from complete loss to high expression, but glypican-1 was detected only in a small subset of breast carcinomas. Expression of all three HSPGs was significantly associated with the Ki67 proliferation index (syndecan-1: p=0.0025; syndecan-4: p<0.0001; glypican-1 p=0.01). Syndecan-1 and syndecan-4 expression correlated with ER negativity, grade, and size of the primary tumors. Syndecan-1 expression (but not syndecan-4 nor glypican-1) predicted patient outcome (DFS: p=0.0054; OS: p=0.0086). However, multivariate analysis failed to identify syndecan-1 as an independent prognostic marker, which was due to its significant association with established prognostic factors. The strong association between cell surface HSPGs and the Ki67 proliferation marker would support a biologic role in carcinoma growth regulation. Furthermore, the close correlation between syndecan expression and negative ER status raises the possibility of hormonal regulation or more likely an association with an aggressive, ER-negative carcinoma phenotype.


breast neoplasm cell adhesion receptors glypican growth factor receptors proteoglycan syndecan 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



Satoshi Kinoshita is acknowledged for his technical assistance in producing the tissue arrays and Sally Drew for performing the immunohistochemical stains. We also thank Dr. Caroline Alexander for helpful discussions. This work was in part funded by grants from the Susan G. Komen Foundation (BCTR0402969) and the␣National institutes of Health (R01-CA107012). The funding sources did not influence the study design. The departmental translational research initiative in pathology (TRIP lab) also contributed to this study.


  1. 1.
    Barbareschi M, Maisonneuve P, Aldovini D, et al., 2003; High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis Cancer 98:474–483PubMedCrossRefGoogle Scholar
  2. 2.
    Leivonen M, Lundin J, Nordling S, et al., 2004; Prognostic value of syndecan-1 expression in breast cancer Oncology 67:11–18PubMedCrossRefGoogle Scholar
  3. 3.
    Kleeff J, Ishiwata T, Kumbasar A, et al., 1998; The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer J Clin Invest 102:1662–1673PubMedCrossRefGoogle Scholar
  4. 4.
    Matsuda K, Maruyama H, Guo F, et al., 2001; Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells Cancer Res 61:5562–5569PubMedGoogle Scholar
  5. 5.
    Guimond SE, Turnbull JE, 1999; Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides Curr Biol 9:1343–1346PubMedCrossRefGoogle Scholar
  6. 6.
    Schlessinger J, Plotnikov AN, Ibrahimi OA, et al., 2000; Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization Mol Cell 6:743–750PubMedCrossRefGoogle Scholar
  7. 7.
    Mundhenke C, Meyer K, Drew S, et al., 2002; Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas Am J Pathol 160:185–194PubMedGoogle Scholar
  8. 8.
    Beauvais DM, Burbach BJ, Rapraeger AC, 2004; The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells J Cell Biol 167:171–181PubMedCrossRefGoogle Scholar
  9. 9.
    Burbach BJ, Ji Y, Rapraeger AC, 2004; Syndecan-1 ectodomain regulates matrix-dependent signaling in human breast carcinoma cells Exp Cell Res 300:234–247PubMedCrossRefGoogle Scholar
  10. 10.
    Wolberg WH, Street WN, 2002; Computer-generated nuclear features compared with axillary lymph node status and tumor size as indicators of breast cancer survival Hum Pathol 33:1086–1091PubMedCrossRefGoogle Scholar
  11. 11.
    Dalton LW, Pinder SE, Elston CE, et al., 2000; Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement Mod Pathol 13:730–735PubMedCrossRefGoogle Scholar
  12. 12.
    Qiao D, Meyer K, Mundhenke C, et al., 2003; Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis J Biol Chem 278:16045–16053PubMedCrossRefGoogle Scholar
  13. 13.
    David G, Bai XM, Van der Schueren B, et al., 1992; Developmental changes in heparan sulfate expression: in situ detection with mAbs J Cell Biol 119:961–975PubMedCrossRefGoogle Scholar
  14. 14.
    David G, Lories V, Decock B, et al., 1990; Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate proteoglycan from human lung fibroblasts J Cell Biol 111:3165–3176PubMedCrossRefGoogle Scholar
  15. 15.
    Harvey JM, Clark GM, Osborne CK, et al., 1999; Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17:1474–1481PubMedGoogle Scholar
  16. 16.
    Burbach BJ, Friedl A, Mundhenke C, et al., 2003; Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells Matrix Biol 22:163–177PubMedCrossRefGoogle Scholar
  17. 17.
    Kato M, Saunders S, Nguyen H, et al., 1995; Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells Mol Biol Cell 6:559–576PubMedGoogle Scholar
  18. 18.
    Leppa S, Vleminckx K, Van Roy F, et al., 1996; Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent J Cell Sci 109(Pt 6):1393–1403PubMedGoogle Scholar
  19. 19.
    Rasbridge SA, Gillett CE, Sampson SA, et al., 1993; Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma J Pathol 169:245–250PubMedCrossRefGoogle Scholar
  20. 20.
    Zhao H, Langerod A, Ji Y, et al., 2004; Different gene expression patterns in invasive lobular and ductal carcinomas of the breast Mol Biol Cell 15:2523–2536PubMedCrossRefGoogle Scholar
  21. 21.
    Filmus J, 2001; Glypicans in growth control and cancer Glycobiology 11:19R–23RPubMedCrossRefGoogle Scholar
  22. 22.
    Zellweger T, Ninck C, Mirlacher M, et al., 2003; Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer Prostate 55:20–29PubMedCrossRefGoogle Scholar
  23. 23.
    Zellweger T, Ninck C, Bloch M, et al., 2005; Expression patterns of potential therapeutic targets in prostate cancer Int J Cancer 113:619–628PubMedCrossRefGoogle Scholar
  24. 24.
    Alexander CM, Reichsman F, Hinkes MT, et al., 2000; Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice Nat Genet 25:329–332PubMedCrossRefGoogle Scholar
  25. 25.
    Woods A, Couchman JR, 2001; Syndecan-4 and focal adhesion function Curr Opin Cell Biol 13:578–583PubMedCrossRefGoogle Scholar
  26. 26.
    Beauvais DM, Rapraeger AC, 2003; Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells Exp Cell Res 286:219–232PubMedCrossRefGoogle Scholar
  27. 27.
    Jaakkola P, Maatta A, Jalkanen M, 1998; The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner Oncogene 17:1279–1286PubMedCrossRefGoogle Scholar
  28. 28.
    Maatta A, Jaakkola P, Jalkanen M, 1999; Extracellular matrix-dependent activation of syndecan-1 expression in keratinocyte growth factor-treated keratinocytes J Biol Chem 274:9891–9898PubMedCrossRefGoogle Scholar
  29. 29.
    Porter D, Lahti-Domenici J, Keshaviah A, et al., 2003; Molecular markers in ductal carcinoma in situ of the breast Mol Cancer Res 1:362–375PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Füsun Baba
    • 1
    • 4
  • Kathryn Swartz
    • 1
  • Regina van Buren
    • 1
  • Jens Eickhoff
    • 2
  • Yong Zhang
    • 1
  • William Wolberg
    • 3
  • Andreas Friedl
    • 1
  1. 1.Department of Pathology and Laboratory MedicineUniversity of Wisconsin-MadisonMadisonUSA
  2. 2.Department of Biostatistics and Medical Informatics University of Wisconsin-MadisonMadisonUSA
  3. 3.Department of SurgeryUniversity of Wisconsin-MadisonMadisonUSA
  4. 4.School of MedicineHarran UniversitySanliurfaTurkey

Personalised recommendations